Announcements Trials

Browse Landscape

Phase

Status

Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 15 Breast Neoplasms 13 Ovarian Neoplasms 5 Stomach Neoplasms 4 Esophageal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Triple Negative Breast Neoplasms 3 Small Cell Lung Carcinoma 3 Neoplasm Metastasis 3 Esophageal Squamous Cell Carcinoma 3 Uterine Cervical Neoplasms 2 Neoplasms 2 Melanoma 2 Advanced Pancreatic Cancer 2 Thoracic Neoplasms 1 Stage IA Pancreatic Adenocarcinoma 1 Squamous Cell Carcinoma of Lung 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Second Line Treatment of Gastric Cancer 1 Sarcoma 1 Resectable Biliary Tract Cancer 1 Pathologic Complete Response 1 Pancreatic Adenocarcinoma 1 Nasopharyngeal Neoplasms 1 Nasopharyngeal Carcinoma 1 Muscle-Invasive Bladder Carcinoma 1 Lung Diseases 1 HR+/HER2- Breast Cancer 1 HER2+ Breast Cancer 1

Interventions

tislelizumab 1 spartalizumab 1 Nivolumab 1 Gemcitabine 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Muscle-Invasive Bladder Carcinoma × Albumin-Bound Paclitaxel × Clear all

NCT04876313 2022-04-06

NURE-Combo

IRCCS San Raffaele

Phase 2 Unknown

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡